Mounjaro®
Starting from £179.99/mo
Start journey Learn moreReduced appetite is one of the most commonly reported effects of tirzepatide. Most people taking Mounjaro find their hunger signals genuinely quieten (sometimes dramatically) within the first few weeks. This is largely intentional: tirzepatide works in part by slowing how quickly food leaves the stomach and by signalling fullness to the brain via GIP and GLP-1 receptors. But not feeling hungry does not mean eating is optional, and that distinction matters more than most people realise when they start. Mounjaro is a prescription-only medicine, and how you eat alongside it is something a prescriber and, where appropriate, a dietitian can help you plan properly.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is the most common misconception our prescribers hear from people starting tirzepatide. The logic seems reasonable, appetite is down, so eating nothing must be better than eating a little. It isn't. Severe caloric restriction, particularly over several weeks, leads the body to lose muscle alongside fat. Muscle is metabolically expensive tissue; lose too much of it and your resting energy expenditure falls, which works against you once treatment ends or doses change.
Clinical trial participants using tirzepatide followed a reduced-calorie diet alongside the medicine, not a near-zero-calorie one. The SURMOUNT-1 trial, published in the New England Journal of Medicine, involved participants eating a structured deficit alongside behavioural support, not fasting. The weight reductions seen in that trial (averaging around 20% at the highest dose) came from a sustainable approach, not from ignoring meals entirely.
A quick habit worth building: before each meal, ask yourself whether you have had at least 20g of protein so far that day. It takes under a minute and keeps muscle protection front of mind even when appetite is low. For practical guidance on what to actually put on the plate, the what to eat on Mounjaro page covers this in detail.
Tirzepatide activates both GIP and GLP-1 receptors, making it the only dual-agonist weight-loss medicine licensed in the UK. Both pathways influence appetite regulation and gastric emptying. The result for most people is that meals feel satisfying much faster, and the gap between meals feels longer before hunger returns, if it returns at all in the early weeks.
The effect is not uniform. Some people notice a significant reduction from their first pen at 2.5mg. Others find hunger suppression arrives more noticeably once the dose increases. A smaller group finds appetite suppression is blunter than they expected; if that describes you, the still feeling hungry on Mounjaro page addresses what might be going on. And a few people experience appetite reduction that feels almost total, which brings its own problems, explored in the next section.
The NHS tirzepatide patient information page notes nausea and reduced appetite among the most commonly reported effects, particularly in the early weeks and after dose increases. That timing matters: what feels overwhelming at week two often settles.
There is a difference between reduced appetite (eating smaller portions and feeling satisfied sooner) and appetite disappearing so completely that eating anything feels impossible. The latter is worth flagging to your prescriber rather than assuming it is simply part of the process.
Consistently eating very little can cause fatigue, dizziness, hair thinning and, over time, nutrient deficiencies that blood tests may not catch immediately. Dehydration is a related risk: people who are not eating often drink less too, and tirzepatide can cause nausea that compounds this. Staying hydrated matters independently of hunger. If you want to understand more about how hunger typically changes on Mounjaro and what to do when it almost disappears entirely, that is worth reading before your next clinical review. If nausea is making eating difficult rather than reduced appetite doing so, the question is different again, that tends to be dose-related and is covered on the Mounjaro treatment page.
If your appetite has dropped steeply and you are struggling to eat adequate protein and calories, raise it at your next clinical review. At nume, every repeat order goes through a fresh clinical assessment, a real prescriber reads your update, not a tick-box system. That is specifically the kind of signal worth including.
Small, nutrient-dense meals work better than trying to eat normal portions that now feel enormous. Prioritise protein first (meat, fish, eggs, legumes, Greek yoghurt), then vegetables, then everything else. Calorie-dense but low-volume foods (nut butters, avocado, full-fat dairy) can help maintain adequate intake without requiring large volumes of food.
Carbohydrates do not need to be eliminated; the question is which ones. If you are eating very little, spending those calories on refined carbohydrates is a poor trade. For a more detailed breakdown of carbohydrate choices specifically, eating carbs on Mounjaro is worth reading alongside this page.
People sometimes ask about the cost of treatment in the context of appetite changes, specifically whether it is still worth continuing if they barely eat. The short answer is that sustainable fat loss and muscle retention depend on the quality of what you eat, not just the quantity. For context on what private treatment involves financially, the Mounjaro UK price changes page explains how list pricing has shifted and what private prescriptions typically include. Treatment decisions are always worth reviewing with a prescriber, not making unilaterally based on appetite alone.
If you are thinking about whether tirzepatide might be clinically appropriate for you, check your eligibility through a free consultation with our prescribers.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.